Key result
Quinidine and verapamil suppress recurrent ventricular tachyarrhythmias in an ARVC patient with an SCN5A mutation.
Why the study?
The clinical course and management of electrical storm in patients with arrhythmogenic right ventricular cardiomyopathy and SCN5A mutation are not well described.
Case Report (n=1)
Combination therapy with quinidine and verapamil successfully suppressed electrical storm in a patient with arrhythmogenic right ventricular cardiomyopathy and an SCN5A mutation.
Answers are grounded in this paper and cite their sources.
May suggest quinidine-verapamil role in refractory SCN5A-mutated ARVC; hypothesis-generating and requires prospective validation.
We described a case of a 58-year-old man with organic changes consistent with right ventricular cardiomyopathy. He also had a loss-of-function mutation in the cardiac sodium channel gene SCN5A, described in Brugada syndrome. He first presented with non-sustained ventricular tachycardia and was implanted with an implantable cardioverter defibrillator. He remained asymptomatic for 8 years until he developed recurrent episodes of ventricular tachyarrhythmias, which required multiple shocks. The patient was treated with a combination of quinidine and verapamil and since then remained free of arrhythmias.
No takes yet. Share an insight, caveat, or question.
Erkapic et al. (2008) conducted a case report in Arrhythmogenic right ventricular cardiomyopathy and SCN5A mutation with electrical storm (n=1). Quinidine and verapamil was evaluated on Freedom from arrhythmias. Treatment with a combination of quinidine and verapamil successfully suppressed recurrent ventricular tachyarrhythmias in a patient with arrhythmogenic right ventricular cardiomyopathy and an SCN5A mutation.
Synapse has enriched 10 related papers. Consider them for comparative context: